期刊文献+

抗环胍氨酸肽单链噬菌体抗体库的建立

Construction of Single-chain Fragment V Antibody pHEN2 Phagemid Library of Anti-cyclic Cit- rullinated Peptide
下载PDF
导出
摘要 【目的】拟构建并鉴定抗环胍氨酸肽(cyclic citrutlinated peptide,CCP)单链片段V(Single chain Fragment V,ScFv)噬菌体抗体库,为进一步可溶性表达和检测类风湿性关节炎(RA)关节滑膜的CCP表达情况,揭示CCP及其抗体在RA发病中作用奠定基础。【方法】①分离抗CCP抗体阳性患者外周血单个核细胞,提取mRNA并反转录cDNA。扩增免疫球蛋白重链可变区(VH)和轻链可变区(VL)。通过重叠聚合酶链反应(PCR)用连接片段将VH和Vκ/Vλ体外连接成单链抗体基因;SfiⅠ和NotⅠ酶切并与噬菌粒PHEN2连接;将pHEN2ScFv电转至感受态大肠杆菌TG1,建立抗CCp-ScFv噬茵体抗体库;②检测抗CCP-ScFvPHEN2噬菌体的库容、插入效率;【结果】抗CCP-ScFv噬菌体抗体库库容8.76×10^8CFUcfu/mL,插入频率83.3%;插入率83.33%。所插入DNA片断约1180bp。MSPⅠ酶切指纹图谱鉴定也显示多样性。【结论】所构建抗环胍氨酸肽单链噬茵体抗体库库容可满足进一步可溶性表达的要求。 [Objective] To construct and identify of single-chain fragment V antibody(ScFv) pHEN2 pha- gemid library of anti-cyclic citrullinated peptides(CCP), and to further explore the soluble expression of CCP in synovium of rheumatoid arthritis(RA) so as to provide the basis for revealing the role of CCP and antibody in the pathogenesis of RA. [Methods]Peripheral blood mononuclear cells in patients with anti-CCP antibody were isolated for the extraction of mRNA and reverse transcription of cDNA. Immunoglobulin heavy chain variable region(VH) and light chain variable region(VL) were amplified. VH and Vκ/Vλ were linked into ScFv gene with junction segment by using overlapping PCR in vitro. Sfi Ⅰ and Not Ⅰ endonuclease were linked to phagemid pHEN2 which was electrically transformed to competence Escherichia coli. TG1. Anti-CCP-ScFv phagemid antibody library was constructed. The content and insertion rate of anti-CCP-ScFv pHEN2 phagemid were detected. [Results]The content of anti-CCP-ScFv pHEN2 phagemid antibody library was 8.76×10^8 CFU cfu/ml, and the insertion rate was 83. 330//oo. The inserted DNA fragment was ll80bp. MSP Ⅰ endonuclease fingerprinting identification showed the diversity. [Conclusion]The content of ScFv pHEN2 phagemid library of anti-CCP can meet the demand of further soluble expression.
出处 《医学临床研究》 CAS 2013年第10期1873-1877,共5页 Journal of Clinical Research
基金 国家自然科学基金(30760235)
关键词 细菌噬菌体 抗体 肽类 Bacteriophages Antibodies Peptides
  • 相关文献

参考文献16

  • 1李鸿斌,张奉春.B淋巴细胞克隆清除治疗类风湿关节炎的研究进展[J].中华医学杂志,2005,85(42):3021-3024. 被引量:4
  • 2Schellekens GA, Visser H, de Jong BA, a al . The diagnostic properties of rheumatoid arthritis antibodies recognizing a ey clic citrullinated peptide[J]. Arthritis Rheum , 2000,43 (1) : 155-163.
  • 3Sehellekens GA, de Jong BA, van den Hoogen FH, a al . Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies[J]. J Clin Invest ,1998,101(1) :273-281.
  • 4Avouae J, Gossec L, Dougados M. Diagnostic and predictive value of anti-cyclic citrullinated protein antibodies in rheuma- toid arthritis: a systematic literature review[J]. Ann Rheum Dis ,2006,65(7) :845-851.
  • 5del Val del Amo N, Ibanez Bosch R, Fito Manteea C, et al .Anti-cyclic citrullinated peptide antibody in rheumatoid arthri- tis relation with disease aggressiveness E J - Clin Exp Rheumatol ,2006,24(3) :281-286.
  • 6Berglin E, Johansson T, Sundin U, et al . Radiological out- come in rheumatoid arthritis is predicted by presence of anti- bodies against cyclic citrullinated peptide before and at disease onset, and by IgA-RF at disease onset[J]. Ann Rheum Dis , 2006,65(4) ,453-458.
  • 7Quinn MA, Gough AK, Green MJ, e al . Anti-CCP antibod ies measured at disease onset help identify seronegative rheu matoid arthritis and predict radiologieal and functional out come[J]. Rheumatology (Oxford) , 2006,45 (4) : 478-480.
  • 8Vossenaar ER, Despres N, Lapointe E, et al . Rheumatoid arthritis specific anti-Sa antibodies target citrullinated vimen- tin[J]. Arthritis Res Ther , 2004, 6 (2) : R142-150. 1.
  • 9Vander Cruyssen B, Cantaert T, Nogueira L, et al . Diagnos- tic value of anti-human citrullinated fihrinogen ELISA and comparison with four other anti-citrullinated protein assays [J]. Arthritis Res Ther ,2006,8(4):R122.
  • 10Feist E, Burmester GR. Citrullinated antigens just diagnos- tic tools or pathogenic targets in rheumatoid arthritis[J]? J Rheumatol ,2006,33(11) 2103-2104.

二级参考文献29

  • 1Edwards JC, Cambridge G. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology (Oxford), 2001,40:205-211.
  • 2De Vita S, Zaja F,Sacco S, et al. Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis. Arthritis Rheum,2002, 46:2029-2033.
  • 3Leandro MJ, Edwards JCW, Cambridge G.Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion. Ann Rheum Dis,2002,61:883-888.
  • 4Edwards JC, Szczepanski L, Szechinski J, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med,2004,17,350:2572-2581.
  • 5Hainsworth JD. Safety of rituximab in the treatment of B cell malignancies: implications for rheumatoid arthritis.Arthritis Res Ther, 2003,5:S12-16.
  • 6Cambridge G, Leandro MJ, Edwards JC,et al. Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis Rheum, 2003,48:2146-2154.
  • 7Szczepan′ ski L, Szechin′ ski J, Filipowicz-Sosnowska A,et al.Infusions of rituximab in patients with rheumatoid arthritis are well tolerated. Ann Rheum Dis, 2003, (Suppl 1):171.
  • 8Moore J, Ma D, Will R,et al. A phase II study of Rituximab in rheumatoid arthritis patients with recurrent disease following haematopoietic stem cell transplantation. Bone Marrow Transplant,2004,34:241-247.
  • 9Bridges SL. Update on autoantibodies in rheumatoid arthritis.Curr Rheumatol Rep,2004,6:343-350.
  • 10Ng YC, Peters DK, Walport MJ. Monoclonal rheumatoid factor-IgG immune complexes. Poor fixation of opsonic C4 and C3 despite efficient complement activation. Arthritis Rheum,1988,31:99-107.

共引文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部